Hoe verhoudt SRGA.Q's PS Ratio zich tot zijn concurrenten?

SRGA.Q is een goede waarde op basis van zijn Price-To-Sales Ratio (0x) vergeleken met het gemiddelde van gelijken (3.8x).

Hoe verhoudt SRGA.Q's PS Ratio zich tot andere bedrijven in de US Medical Equipment industrie?

SRGA.Q is een goede waarde op basis van de Price-To-Sales -ratio ( 0 x) vergeleken met het US Medical Equipment -industriegemiddelde ( 3.3 x).

Wat is SRGA.Q's PS Ratio vergeleken met zijn Fair PS Ratio? Dit is de verwachte PS Ratio, rekening houdend met de verwachte winstgroei van het bedrijf, winstmarges en andere risicofactoren.

Onvoldoende gegevens om de Price-To-Sales Fair Ratio van { SRGA.Q te berekenen voor waarderinganalyse.

Wat is de reële prijs van SRGA.Q als we kijken naar de toekomstige kasstromen? Voor deze schatting gebruiken we een Discounted Cash Flow-model.

Onvoldoende gegevens om de reële waarde van SRGA.Q te berekenen voor waarderingsanalyse.

Wat is de 12-maandsprognose van de analisten en hebben we enig statistisch vertrouwen in het consensuskoersdoel?

Er zijn onvoldoende gegevens om een prijsvoorspelling te tonen.

Surgalign Holdings (OTCPK:SRGA.Q) - Aandelenkoers, Nieuws & Analyse

SRGA.Q Overzicht aandelen

Surgalign Holdings, Inc., a medical technology company, develops, manufactures, distributes, and markets spinal hardware implants and biomaterial products worldwide. Meer informatie

SRGA.Q fundamentele analyse
Sneeuwvlok Score
Waardering	2/6
Toekomstige groei	0/6
Prestaties in het verleden	0/6
Financiële gezondheid	0/6
Dividenden	0/6

Risicoanalyse

De winst is de afgelopen 5 jaar met 9.6% per jaar gedaald

Heeft geen betekenisvolle marktkapitalisatie ( $165K )

Negatief eigen vermogen

Zeer volatiele aandelenkoers in de afgelopen 3 maanden

+ 2 meer risico's

Surgalign Holdings, Inc. Concurrenten

Procyon

OTCPK:PCYN

US$1.6m

InVitro International

OTCPK:IVRO

US$1.8m

Vycor Medical

OTCPK:VYCO

US$2.5m

Arch Therapeutics

OTCPK:ARTH

US$888.9k

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Surgalign Holdings
Historische aandelenkoersen
Huidige aandelenkoers	US$0.018
52 Week Hoogtepunt	US$4.00
52 Week Laag	US$0.005
Bèta	1.49
11 maand verandering	63.64%
3 maanden verandering	-80.00%
1 Jaar Verandering	-99.50%
33 jaar verandering	-99.97%
5 jaar verandering	-99.99%
Verandering sinds IPO	-100.00%

Recent nieuws en updates

Recent updates

Surgalign stock rises 7% after receiving FDA clearance of Cortera spinal fixation system

Aug 24

Rendement voor aandeelhouders

	SRGA.Q	US Medical Equipment	US Markt
7D	16.1%	1.5%	2.2%
1Y	-99.5%	20.8%	31.6%

Rendement versus industrie: SRGA.Q presteerde slechter dan de US Medical Equipment -sector, die het afgelopen jaar een rendement van 20.8 % opleverde.

Rendement versus markt: SRGA.Q presteerde slechter dan US Market, dat het afgelopen jaar een rendement van 31.6 % opleverde.

Prijsvolatiliteit

Is SRGA.Q's price volatile compared to industry and market?
SRGA.Q volatility
SRGA.Q Average Weekly Movement	40.5%
Medical Equipment Industry Average Movement	8.1%
Market Average Movement	6.3%
10% most volatile stocks in US Market	15.7%
10% least volatile stocks in US Market	3.1%

Stabiele aandelenkoers: De aandelenkoers van SRGA.Q is de afgelopen 3 maanden volatiel geweest.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit van SRGA.Q is het afgelopen jaar gestegen van 28% naar 40%.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
1997	240	Terry Rich	www.surgalign.com

Surgalign Holdings, Inc. Samenvatting

Hoe verhouden de winst en inkomsten van Surgalign Holdings zich tot de beurswaarde?
SRGA.Q fundamentele statistieken
Marktkapitalisatie	US$165.30k
Inkomsten(TTM)	-US$50.49m
Inkomsten(TTM)	US$78.12m

0.0x

P/S-verhouding

0.0x

Koers/Winstverhouding

Is SRGA.Q overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
SRGA.Q resultatenrekening (TTM)
Inkomsten	US$78.12m
Kosten van inkomsten	US$26.03m
Brutowinst	US$52.09m
Overige uitgaven	US$102.58m
Inkomsten	-US$50.49m

Laatst gerapporteerde inkomsten

Mar 31, 2023

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	-5.50
Brutomarge	66.68%
Nettowinstmarge	-64.63%
Schuld/Eigen Vermogen Verhouding	-54.1%

Hoe presteerde SRGA.Q op de lange termijn?

Bekijk historische prestaties en vergelijking

SRGA.Q Overzicht aandelen

Risicoanalyse

Surgalign Holdings, Inc. Concurrenten

OTCPK:PCYN

US$1.6m

OTCPK:IVRO

US$1.8m

OTCPK:VYCO

US$2.5m

OTCPK:ARTH

US$888.9k

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Surgalign Holdings, Inc. Files Form 15

Xtant Medical Holdings, Inc. (NYSEAM:XTNT) acquired NanOss Production Operations of RTI Surgical, Inc. for $2 million.

Xtant Medical Holdings, Inc. (NYSEAM:XTNT) completed the acquisition of Certain assets from Surgalign Holdings, Inc. (NasdaqGS:SRGA).

Surgalign Holdings, Inc.(NasdaqGS:SRGA) dropped from S&P TMI Index

Xtant Medical Holdings, Inc. (NYSEAM:XTNT) entered into asset purchase agreement to acquire Certain assets from Surgalign Holdings, Inc. (NasdaqGS:SRGA) for $5 million.

Surgalign Holdings, Inc. Filed for Bankruptcy

Recent updates

Surgalign Holdings, Inc. Files Form 15

Xtant Medical Holdings, Inc. (NYSEAM:XTNT) acquired NanOss Production Operations of RTI Surgical, Inc. for $2 million.

Xtant Medical Holdings, Inc. (NYSEAM:XTNT) completed the acquisition of Certain assets from Surgalign Holdings, Inc. (NasdaqGS:SRGA).

Surgalign Holdings, Inc.(NasdaqGS:SRGA) dropped from S&P TMI Index

Xtant Medical Holdings, Inc. (NYSEAM:XTNT) entered into asset purchase agreement to acquire Certain assets from Surgalign Holdings, Inc. (NasdaqGS:SRGA) for $5 million.

Surgalign Holdings, Inc. Filed for Bankruptcy

Surgalign Holdings Receives Deficiency Letter from the Nasdaq Stock Market LLC Due to Non-Compliance with Minimum Market Value of Publicly Held Shares

Price target decreased by 19% to US$2.22

Consensus estimates of losses per share improve by 87%

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Surgalign Holdings, Inc. Announces Release of HOLO AI Insights for Neurovascular Research

Surgalign Holdings, Inc. to Report Q1, 2023 Results on May 11, 2023

Consensus revenue estimates fall by 38%

Full year 2022 earnings: EPS misses analyst expectations

Surgalign Holdings, Inc. Announces 100th Case Completed Utilizing its Recently Launched Cortera™ Spinal Fixation System

Surgalign Holdings, Inc. has completed a Follow-on Equity Offering in the amount of $11.99474 million.

Price target decreased to US$5.00

Consensus EPS estimates fall by 14%

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target decreased to US$11.00

Surgalign Holdings, Inc. Lowers Revenue Guidance for 2022

Surgalign Holdings, Inc. to Report Q3, 2022 Results on Nov 02, 2022

Surgalign Holdings, Inc Launches Portfolio of Fortilink® with TiPlus™ Technology Products, Expanding its Addressable Market for Interbody Fusion Procedures

Surgalign Holdings, Inc. Announces Third Clinical Site in the Commercialization of Its Holo Portal™ Surgical Guidance System

Surgalign Announces FDA 510(K) Clearance of the Cortera Spinal Fixation System – the Company’s New Flagship Posterior Fixation Platform

Surgalign stock rises 7% after receiving FDA clearance of Cortera spinal fixation system

Surgalign Holdings Announces Asset Impairment for the Second Quarter Ended June 30, 2022

Surgalign revenue of $20.62M misses by $0.51M, reconfirms full-year revenue

Surgalign Holdings, Inc. Appoints Paolo Amoruso as New General Counsel and Corporate Secretary

Surgalign Holdings, Inc. Reaches Settlement with the Securities and Exchange Commission

Surgalign Holdings, Inc. to Report Q2, 2022 Results on Aug 09, 2022

Surgalign Holdings, Inc. Announces Clinical Site Expansion in the Commercialization of Its HOLO Portal Surgical Guidance System in Ohio

Chief Financial Officer recently bought US$100k worth of stock

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Surgalign Holdings, Inc. Revises Revenue Guidance for the Fiscal Year 2022

Surgalign™ Announces the First Successful Surgical Procedure Utilizing Its HOLO Portal™ Surgical Guidance System

Price target decreased to US$1.00

Surgalign Holdings, Inc., Annual General Meeting, May 10, 2022

Joshua H. Derienzis Notifies Surgalign Holdings, Inc. of His Decision to Resign from His Position as Chief Legal Officer and Corporate Secretary, Effective May 10, 2022

Consensus forecasts updated

Full year 2021 earnings: EPS and revenues exceed analyst expectations

Surgalign Holdings, Inc. Appoints David Lyle as Chief Financial Officer

Surgalign Holdings, Inc. Receives FDA Clearance for HOLO Portal™ System

Surgalign Holdings - A Future Of Digital Surgery

Price target decreased to US$2.85

Third quarter 2021 earnings released: US$0.06 loss per share (vs US$0.36 loss in 3Q 2020)

Sizing Up Surgalign

Independent Director Jeffrey Lightcap has left the company

Chairman Stuart Simpson has left the company

Surgalign Holdings: Insiders Are Buying

Surgalign Holdings, Inc. Announces Issuance of U.S. Patent Covering the Use of Artificial Intelligence in Medical Image Segmentation

President recently bought US$1.0m worth of stock

Surgalign Holdings: Pinocchio Has A Happy Ending

Second quarter 2021 earnings released: US$0.086 loss per share (vs US$0.30 loss in 2Q 2020)

Price target decreased to US$4.21

Surgalign Holdings: A Marketing Ploy

Surgalign Holdings, Inc.(NasdaqGS:SRGA) dropped from Russell 3000E Value Index

Surgalign reports inducement grants under Nasdaq listing rule

First quarter 2021 earnings released: US$0.15 loss per share (vs US$0.24 loss in 1Q 2020)

Surgalign Spine Technologies Submits Premarket Notification 510(K) of Its Digital Surgical Guidance System